NCT02141919Active, not recruitingPhase 2
Stereotactic Ablative Body Radiation Therapy for Patients With Primary Renal Cancer
A Phase II Trial of Stereotactic Ablative Body Radiation Therapy (SABR) for Patients With Primary Renal Cancer (RCC)
Source: ClinicalTrials.gov · Last updated 26 Dec 2025
Brief summary (registry, in English)
The goal of this phase II clinical trial is to evaluate the efficacy of the completely non-invasive treatment option of stereotactic radiation therapy for the treatment of biopsy proven and growing small renal tumors.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- First submitted
- 12 May 2014
- Start date
- Jun 2013
- Primary completion date
- May 2026
- Lead sponsor
- University of Texas Southwestern Medical Center
- Diseases
- Kidney cancer
- NCT number
- NCT02141919
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 16
- From Jun 2013 to the primary completion date, May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subject has received any treatment for the treating renal mass; such as RFA or cyroablation.
- If other renal masses received RFA or cryoablation or surgery, then these patients are eligible.
- Subjects received previous abdominal radiation
- Evidence of Metastatic Disease, unless disease-free for ≥ 3 years prior to registration, (non-melanomatous skin cancer and in-situ cancers are okay).
Other
- Female subjects who are pregnant or planning to become pregnant during the course of SABR.
Who the study is looking for
- Age ≥ 18 years.
- Renal mass ≤ 5cm
- The treating renal mass must be ≤ 5cm. Other renal masses (cysts etc.) of any size will not make the subject ineligible
- Biopsy proven Renal neoplasm
- All histology of renal cancers are included including oncocytoma
- Growth of renal mass \>2mm in radiographic scans must be demonstrated within a one year period.
- Ability to understand and the willingness to sign a written informed consent.
- Subject is able to undergo either an MRI or administration of contrast agent for CT
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of the study. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
- Has not undergone a hysterectomy or bilateral oophorectomy; or
- Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Texas, Southwestern Coordinator of this site? Confirm its status | Dallas | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.